Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study
Volume
30
Pagination
90 - 90
Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
ISSN
0815-9319
Metadata
Show full item recordAuthors
Pianko, S; Cooper, C; Brown, A; Forton, D; Nahass, R; George, J; Barnes, E; Brainard, D; Massetto, B; Lin, MURI
http://www.gastrojournal.org/article/S0016-5085%2815%2901069-0/abstracthttp://qmro.qmul.ac.uk/xmlui/handle/123456789/11123
Collections
- College Publications [5164]
